Prediction, prevention, and treatment of delirium from the perspective of neuroinflammation

2016 Fiscal Year Final Research Report

• Project/Area Number: 26461773
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Psychiatric science
• Research Institution: Juntendo University
• Principal Investigator: Hatta Kotaro 順天堂大学, 医学部, 教授 (90337915)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: スボレキサント / せん妄 / 予防 / 臨床試験 / オレキシン

Outline of Final Research Achievements

We examined whether suvorexant, a potent and selective orexin receptor antagonist, is effective for the prevention of delirium.Method: We conducted a multi-center, rater-blinded, randomized placebo-controlled clinical trial in intensive care units and regular acute wards between April 2015 and March 2016. Eligible patients were 65-89 years old and newly admitted due to emergency. Seventy-two patients were randomly assigned to receive suvorexant (15 mg/day; 36 patients) and placebo (36 patients) every night for three days. The primary outcome measure was incidence of delirium as determined by the DSM-5. Trained psychiatrists assessed for delirium. We found that development of delirium occurred significantly less often among patients taking suvorexant than those taking placebo (0% [n/N=0/36] vs. 17% [6/36], P=.025). Suvorexant administered nightly to elderly patients admitted for acute care may provide protection against delirium.

Free Research Field

精神医学